Deck
Zydus Wellness · ZYDUSWELL · NSE
Zydus Wellness owns near-monopoly Indian consumer-health brands — Sugar Free, Glucon-D, Complan, Nycil, Everyuth — distributed through 2.8 million outlets and tied to a Heinz-era acquisition that still drags reported returns.
₹508
Price
₹16,150 Cr
Market cap
₹3,389 Cr
Revenue (TTM)
69.6%
Promoter holding
Listed BSE 2005; compounded for two decades to a split-adjusted peak in Sep-2025, then drew down to ₹357 by Mar-2026 on the Comfort Click leverage shock; has since retraced 42% to ₹508.
2 · The 3-day binary
Three days from now, the May 18 print is the first hard test of whether the 42% bounce has substance.
- The print. Q4 FY26 results and the conference call land Monday, May 18, 2026. Three answers matter: Comfort Click's standalone EBITDA margin, the bridge-loan refinancing structure, and whether Q4 organic revenue cleared low-teens consensus.
- What's at stake. Bull conditions need Comfort Click above 14% EBITDA and refinancing emerging sub-7% with no equity component. Bear conditions trigger if either lever fails — back-to-back Q2 and Q3 FY26 net losses have already put credit standing in play.
- The silence. The ₹3,042 Cr bridge loan matures in early FY27 and management has disclosed no refinancing terms in eight months. Continued silence past Monday is itself a signal — equity-linked refinancing remains the bear's base case until proven otherwise.
Three answers, one print. The market has priced a smooth recovery; Monday tests every line of that argument.
3 · The thesis tension
A 78× P/E on a 6% ROCE — accounting illusion, or seven years of capital destruction?
- Bull read. Reported earnings hide non-cash amortisation on ₹5,000 Cr of Heinz-era intangibles. Normalised earnings power is ₹450–500 Cr, implying a real P/E of 32–36× — defensible for a portfolio of category-leading brands (Sugar Free 95.9% share, Glucon-D 58.8%, Everyuth scrub 48.5%).
- Bear read. ROCE has been stuck at 5–6% every year since FY2020. Emami earns 32%, Marico 47%, Nestlé India 85% — all at lower or comparable P/E. A 6% return after seven years of Heinz integration says the moat exists in brand share, not enterprise economics.
- What decides it. Tangible ROE (ex-goodwill) across the next four quarters. Above 15% supports the bull read and the multiple compresses naturally as amortisation runs off. Stuck below 10% would suggest the FY23-onwards 17–18% EBITDA target — now restated three times — is the regime, not a transition.
Both sides agree on the brands. They disagree on whether the brands ever earn their cost of capital.
4 · The money picture
Borrowings jumped 16× in one half-year; operating margin halved; cash conversion has run the wrong way for five years.
₹3,042 Cr
Borrowings (Sep-2025)
from ₹188 Cr in Mar-2025
6%
Q3 FY26 op margin
vs 21% in Q4 FY25
0.78×
3-yr CFO / Net Income
FY23 dropped to 0.30×
75 days
Cash conversion cycle
FY18: -135 days
The Comfort Click acquisition (£134M UK supplements business, ~₹2,810 Cr at 5% bridge) loaded the balance sheet with debt the market hasn't fully priced. Cash to service it isn't there yet — receivables grew ~30% YoY against ~16% revenue growth in FY25, DSO has run from 18 to 49 days since FY21, and working capital has structurally inverted from supplier-funded to self-funded. Whether that reverses in the FY26 cash flow statement is the single signal that tells you whether the bridge gets refinanced with debt — or with shareholders.
5 · Bull & Bear
Lean cautious — the brands are real, but the next four quarters decide whether the balance sheet survives the bet on Comfort Click.
- For. Five franchise brands hold #1 share in their niches; Sugar Free at ~96% is a near-monopoly. Gross margin has recovered 361 bps over two years to ~57% — the operating-leverage thesis is at least directionally working.
- For. Comfort Click pushed consolidated gross margin to 63.3% in Q3 FY26 and management called the deal cash-EPS accretive; a normal 2026 summer plus a clean Q4 print would support a re-rating case toward ₹650.
- Against. ROCE has been 5–6% for five consecutive years and management has restated the 17–18% EBITDA target multiple times; the ROE 10% goal set in FY24 was quietly dropped. Forecast-to-delivery track record is poor.
- Against. ₹3,042 Cr bridge loan, no disclosed refinancing terms three days before earnings, two consecutive loss quarters in credit-market memory. Even a 5% equity component would dilute a thin float at the worst possible moment — and True North exited its 2.67% stake as the new debt cycle began.
My view — the franchise is real but the proof window is right now. Watchlist until Monday clarifies refinancing and the 2026 summer delivers something other than a third consecutive washout.
Watchlist to re-rate: Refinancing structure (pure debt vs equity-linked) at the May 18 call; DSO below 45 days in the Q4 FY26 balance sheet; Glucon-D and Nycil volume growth above 10% in the Q1 FY27 print (Aug-2026).